Johnson & Johnson (JNJ) said Friday that it plans to increase its US investment to more than $55 billion over the next four years to boost its manufacturing and research capabilities.

The healthcare products conglomerate said the investment represents a 25% increase compared with the previous four years and covers manufacturing, research and development, and technology.

Johnson & Johnson aims to build three new manufacturing plants and expand several sites related to its innovative medicine and MedTech businesses. The plan includes R&D investments to develop treatments in areas such as oncology, neuroscience, immunology, cardiovascular disease, and robotic surgery.

The move comes as companies, including in the pharmaceutical industry, face uncertainty amid US tariff plans. Last month, Eli Lilly (LLY) announced a plan to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the US.

In a separate statement on Friday, Johnson & Johnson said it will break ground on its new biologics manufacturing facility in Wilson, North Carolina. The plant will boost the company's capacity to deliver medicines treating cancer, immune-mediated and neurological diseases.

"Our increased US investment begins with the ground-breaking of a high-tech facility in North Carolina that will not only add US-based jobs but manufacture cutting-edge medicines to treat patients in America and around the world," Johnson & Johnson Chief Executive Joaquin Duato said in a statement.